A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer

Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).

(2019) Efrat Dotan et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

(2017) Eileen Mary O'Reilly et al.   JOURNAL OF CLINICAL ONCOLOGY

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

(2017) Marcus M. Fischer et al.   Science Advances

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

(2016) CHUN ZHANG et al.   CANCER RESEARCH

Wnt signaling in cancer

(2016) T Zhan et al.   ONCOGENE

The WNT system: background and its role in bone

(2015) U. H. Lerner et al.   JOURNAL OF INTERNAL MEDICINE

Discovery and Optimization of a Porcupine Inhibitor

(2015) Athisayamani Jeyaraj Duraiswamy et al.   JOURNAL OF MEDICINAL CHEMISTRY

An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control

(2014) H. Clevers et al.   SCIENCE

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

(2013) Philippe Rougier et al.   EUROPEAN JOURNAL OF CANCER

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

(2012) A. Gonçalves et al.   ANNALS OF ONCOLOGY

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The therapeutic promise of the cancer stem cell concept

(2010) Natasha Y. Frank et al.   JOURNAL OF CLINICAL INVESTIGATION

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY